Cannabis may not be suitable for all patients. Several publications from Health Canada, the CFPC, and others, have identified a set of special-risk populations in the context of both medical and recreational cannabis use. 1,2,3,4,5,6,7,8 More Level 1 research is needed on both the therapeutic and adverse effects of cannabis for specific presentations and populations.
This resource provides an overview of the risks of cannabis use in the following commonly-cited populations:
Canadian Paediatric Society Position Statement: Is the medical use of cannabis a therapeutic option for children? (February 2016)
Canadian Paediatric Society Position Statement: Cannabis and Canada’s children and youth (May 2017)
1 Hodgson, C, Zacharias R. Who shouldn’t use cannabis?: Evidence Brief. Michael G. DeGroote Centre for Medical Cannabis Research. Hamilton, ON; 2017. cited 26 Sep 2018.
2 Fischer B, Russell C, Sabioni P, van den Brink W, Le Foll B, Hall W, et al. Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. Public Health Policy. 2017;107(8):e1-e12.
3 Kahan M, Srivastava A, Spithoff S, Bromley L. Prescribing smoked cannabis for chronic noncancer pain. Canadian Family Physician. 2014;60:1083-1090.
4 Government of Canada. Is cannabis safe to use? Facts for young adults aged 18-25 years: Cannabis evidence Brief. Health Canada. Ottawa, ON; 2018 cited 26 Sep 2018.
5 Government of Canada Evidence Brief: Is cannabis safe to use? Facts for youth aged 13-17 years: Cannabis evidence Brief. Health Canada. Ottawa, ON; 2018 cited 26 Sep 2018.
6 Government of Canada Evidence Brief: Is cannabis safe during preconception, pregnancy, and breastfeeding?: Cannabis evidence Brief. Health Canada. Ottawa, ON; 2018 cited 26 Sep 2018.
7 Lenroot RK, Giedd JN. Brain development in children and adolescents: Insights from anatomical magnetic resonance imaging. Neurosci Biobehav Rev 2006;30(6):718–29.
8 Government of Canada. Does cannabis use increase the risk of developing psychosis or schizophrenia?: Cannabis evidence brief. Health Canada. Ottawa, ON; 2018 cited 26 Sep 2018.
9 Gunn JK, Rosales CB, Center KE, Nunez A, Gibson SJ, Christ C, Ehiri JE. Prenatal exposure to cannabis and maternal and child health outcomes: A systematic review and meta-analysis. BMJ Open 2016 Apr 5; 6(4):e009986,2015-009986
10 Fried P. Ottawa Prenatal Prospective Study, 1995, 2002.
11Day N, Richardson G. Maternal Health Practices and Child Development Study, 1991.
12 Porath AJ, Konefal S, Kent P. Clearing the smoke on cannabis: Maternal cannabis use during pregnancy—an update. Ottawa, ON: Canadian Centre on Substance Use and Addiction; 2018 cited Sep 24 2018.
13 Chabarria KC, Racusin DA, Antony KM, et al. Marijuana use and its effects in pregnancy. Am J Obstet Gynecol 2016;215:506.e1-7.
14 El Marroun H, Tiemeier H, Steegers E, Jaddoe V, Hofman A, Velhulst FC. Intrauterine cannabis exposure affects fetal growth trajectories: The generation R study. Journal of the American Academy of Child & Adolescent Psychiatry Dec 2009; 48(11): 1173-1181.
15 Liston J. Breastfeeding and the use of recreational drugs--alcohol, caffeine, nicotine and marijuana. Breastfeed Rev 1998 Aug;6(2):27-30.
16 Djulus J, Moretti M, Koren G. Marijuana use and breastfeeding. Can Fam Physician. 2005 Mar 10; 51(3): 349–350.
17 Klonoff-Cohen HS, Natarajan L, Chen RV. A prospective study of the effects of female and male marijuana use on in vitro fertilization (IVF) and gamete intrafallopian transfer (GIFT) outcomes. Am J Obstet Gynecol 2006 Feb;194(2):369-76
18 Brents LK. Marijuana, the endocannabinoid system and the female reproductive system. Yale J Biol Med 2016 Jun 27;89(2):175-91. 15.
19 Sharma R, Biedenharn KR, Fedor JM, Agarwal A. Lifestyle factors and reproductive health: Taking control of your fertility. Reprod Biol Endocrinol 2013 Jul 16;11:66,7827-11-66
20 Gundersen TD, Jorgensen N, Andersson AM, Bang AK, Nordkap L, Skakkebaek NE, Priskorn L, Juul A, Jensen TK. Association between use of marijuana and male reproductive hormones and semen quality: A study among 1,215 healthy young men. Am J Epidemiol 2015 Sep 15;182(6):473-81.
21 Grant CN, Belanger RE, Canadian Paediatric Society, Adolescent Health Committee. Position Statement: Cannabis and Canada’s children and youth. Paediatr Child Health 2017;22(2):98-102. cited Sep 21 2018.
22 Jacobus J, Tapert SF. Effects of cannabis on the adolescent brain. Curr Pharm Des. 2014;20(13): 2186–2193.
23 Lisdahl KM, Gilbart ER,Wright NE, Shollenbarger S. Dare to delay? The impacts of adolescent alcohol and marijuana use onset on cognition, brain structure, and function. Front Psychiatry. 2013;4:53.
24 Volkow ND, Swanson JM, Evins AE, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: A Review. Jama Psychiatry 2016 73 (3): 292-97.
25 Rieder MJ. Is the medical use of cannabis a therapeutic option for children? Canadian Pediatric Society Position Statement. Paediatr Child Health 2016; 21 (1): 31-34.
26 Turner SD, Spithoff S, Kahan M. Approach to cannabis use disorder in primary care: Focus on youth and other high-risk users. Can Fam Physician 2014;60(9):801–8, e423–32.
27 Volkow ND, Baler RD, Compton WM, Weiss SR . Adverse health effects of marijuana use. N Engl J Med 2014;370(23):2219–27.
28 Buckner JD, Schmidt NB, Lang AR , Small JW, Schlauch RC, Lewinsohn PM. Specificity of social anxiety disorder as a risk factor for alcohol and cannabis dependence. J Psychiatr Res 2008;42(3):230–9.
29 Cornelius JR , Kirisci L, Reynolds M, Clark DB, Hayes J, Tarter R . PTSD contributes to teen and young adult cannabis use disorders. Addict Behav 2010;35(2):91–4.
30 Johns A. Psychiatric effects of cannabis. Br J Psychiatry 2001;178:116–22.
31 D’Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology 2004;29(8):1558–72.
32 Arendt M, Rosenberg R , Foldager L, Perto G, Munk-Jørgensen P. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: Follow-up study of 535 incident cases. Br J Psychiatry 2005;187(6):510–5.
33 Lynskey MT, Coffey C, Degenhardt L, Carlin JB, Patton G. A longitudinal study of the effects of adolescent cannabis use on high school completion. Addiction 2003;98(5):685–92.
34 Brook JS, Stimmel MA, Zhang C, Brook DW. The association between earlier marijuana use and subsequent academic achievement and health problems: A longitudinal study. Am J Addict 2008;17(2):155–60.
35 Batalla A, Bhattacharyya S, Yucel M, Fusar-Poli P, Crippa JA, Nogue S, Torrens M, Pujol J, Farre M, Martin-Santos R. Structural and functional imaging studies in chronic cannabis users: A systematic review of adolescent and adult findings. PLoS One 2013;8(2):e55821.
36 Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis use and earlier onset of psychosis: A systematic meta-analysis. Arch Gen Psychiatry 2011 Jun;68(6):555-61.
37 Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, Marconi A, La Cascia C, Reis Marques T, Pariante C, et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull 2014 Nov;40(6):1509-17.
38 McGrath J, Welham J, Scott J, et al. Association between cannabis use and psychosis-related outcomes using sibling pairanalysis in a cohort of young adults. Arch Gen Psychiatry. 2010;67(5):440–447.
39 Helle S, Ringen PA, Melle I, Larsen TK, Gjestad R, Johnsen E, Lagerberg TV, Andreassen OA, Kroken RA, Joa I, et al. Cannabis use is associated with 3 years earlier onset of schizophrenia spectrum disorder in a naturalistic, multi-site sample (N=1119). Schizophr Res 2016 Jan;170(1):217-21.
40 Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull 2016 Feb 15.
41 Fergusson DM, Horwood LJ, Ridder EM. Tests of casual linkages between cannabis use and psychotic symptoms. Addiction 2005 Mar;100(3):354-66.
42 Radhakrishnan R, Wilkinson ST, D'Souza DC. Gone to pot - A review of the association between cannabis and psychosis. Front Psychiatry 2014 May 22;5:54.Last Updated: May 11, 2019
You can adjust your cookie settings by navigating the tabs on the left hand side.
These cookies are necessary for the website to function and allow users to log in. Without this type of cookie, our services won't work properly or won't be able to provide certain basic features and functionalities.
This setting cannot be changed.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
These cookies are used to link web visits to social media campaigns conducted through social sites, such as Facebook. Our ad management providers use these cookies to populate an advertisement for us when you visit other websites.
Please enable Strictly Necessary Cookies first so that we can save your preferences!
Google Analytics page views are anonymized, with no personally identifying information. These cookies are used to analyse how visitors use a website, for instance which pages are visited most often, in order to provide a better user experience.
We participate in advertising programs that display advertising about us on other unaffiliated websites (e.g. Facebook). We customize this advertising to you based on your having visited our website.
We use technologies such as cookies and pixels to collect information on how users navigate our website.
If you do not want to receive interest-based advertising on other websites or would like to exercise choices about the third party advertising networks that provide you with interest-based advertising, please see the opt-out options below. Please note that if you opt-out you may still receive online advertising from us on other websites or applications. However, these advertisements will not be displayed to you based on your interests.
Interest-Based Advertising and Analytics. You can opt-out of network advertising programs that track your activities across multiple websites to deliver personalized advertising content to you. Please visit Digital Advertising Alliance of Canada Opt-Out Page, NAI Opt-Out Page and the Ad Choices Opt-Out Page.
Cookies. If you would prefer not to accept cookies, you can: (i) go to your browser settings and change your settings so you are notified when you receive a cookie and you can choose whether or not to accept it; (ii) disable existing cookies by selecting this option in your browser; or (iii) set your browser to automatically reject any cookies. Disabling cookies may negatively impact how oma.org works for you by breaking the “stay signed in” functionality and parts of the “My Account” application.
Privacy Officer150 Bloor St. WSuite 900Toronto, ONM5S 3C1